ELIGIBILITY AND COST OF LOW-DOSE RIVAROXABAN BASED ON COMPASS TRIAL: INSIGHTS FROM THE VETERANS AFFAIRS HEALTHCARE SYSTEM
Akash Kataruka(Veterans Health Administration), Michael E. DeBakey(Emory University), John A. Spertus(Saint Luke's Health System), Dhruv S. Kazi(Veterans Health Administration), Laura Petersen(APLA Health), Salim S. Virani(Aga Khan University), Dhruv Mahtta(Brigham and Women's Hospital), Christie M. Ballantyne(Baylor College of Medicine), Ravi S. Hira(University of Washington), Julia M. Akeroyd(Veterans Health Administration), Deepak L. Bhatt(Mount Sinai Hospital)
Cited by 0
Related Papers
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
|Circulation|2020|9.4k
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
|Circulation|2018|7.2k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k